NCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
Clinical Trials
5 trialsNCT02112526 2024-12-20
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 1 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT04564040 2020-12-29
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
AstraZeneca
Phase 1 Completed
NCT02211014 2020-07-31
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
Acerta Pharma BV
Phase 1 Completed